Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity
- PMID: 39273009
- PMCID: PMC11394638
- DOI: 10.3390/cells13171437
Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity
Abstract
The gut microbiota plays an essential role in maintaining immune homeostasis and influencing the immune landscape within the tumor microenvironment. This review aims to elucidate the interactions between gut microbiota and tumor immune dynamics, with a focus on colorectal cancer (CRC). The review spans foundational concepts of immuno-microbial interplay, factors influencing microbiome composition, and evidence linking gut microbiota to cancer immunotherapy outcomes. Gut microbiota modulates anti-cancer immunity through several mechanisms, including enhancement of immune surveillance and modulation of inflammatory responses. Specific microbial species and their metabolic byproducts can significantly influence the efficacy of cancer immunotherapies. Furthermore, microbial diversity within the gut microbiota correlates with clinical outcomes in CRC, suggesting potential as a valuable biomarker for predicting response to immunotherapy. Conclusions: Understanding the relationship between gut microbiota and tumor immune responses offers potential for novel therapeutic strategies and biomarker development. The gut microbiota not only influences the natural history and treatment response of CRC but also serves as a critical modulator of immune homeostasis and anti-cancer activity. Further exploration into the microbiome's role could enhance the effectiveness of existing treatments and guide the development of new therapeutic modalities.
Keywords: colorectal cancer; gut microbiota; immune modulation; immunotherapy; microbial diversity.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
Similar articles
-
Potential role of the intratumoral microbiota in colorectal cancer immunotherapy.Int Immunopharmacol. 2024 Aug 20;137:112537. doi: 10.1016/j.intimp.2024.112537. Epub 2024 Jun 22. Int Immunopharmacol. 2024. PMID: 38909493 Review.
-
Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.Biomed Pharmacother. 2023 Sep;165:115040. doi: 10.1016/j.biopha.2023.115040. Epub 2023 Jun 24. Biomed Pharmacother. 2023. PMID: 37364479 Review.
-
Gut microbiome as a treatment in colorectal cancer.Int Rev Immunol. 2024;43(4):229-247. doi: 10.1080/08830185.2024.2312294. Epub 2024 Feb 12. Int Rev Immunol. 2024. PMID: 38343353 Review.
-
Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer.Crit Rev Oncol Hematol. 2025 Apr;208:104629. doi: 10.1016/j.critrevonc.2025.104629. Epub 2025 Jan 27. Crit Rev Oncol Hematol. 2025. PMID: 39864533 Review.
-
Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer.Front Immunol. 2022 Nov 8;13:1030745. doi: 10.3389/fimmu.2022.1030745. eCollection 2022. Front Immunol. 2022. PMID: 36426359 Free PMC article. Review.
Cited by
-
The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions.Biology (Basel). 2025 Feb 28;14(3):251. doi: 10.3390/biology14030251. Biology (Basel). 2025. PMID: 40136508 Free PMC article. Review.
-
Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.Int J Mol Sci. 2025 Apr 15;26(8):3733. doi: 10.3390/ijms26083733. Int J Mol Sci. 2025. PMID: 40332367 Free PMC article. Review.
-
Causal relationship between gut microbiota and laryngeal cancer: a mendelian randomization analysis.Braz J Otorhinolaryngol. 2025 Jul-Aug;91(4):101634. doi: 10.1016/j.bjorl.2025.101634. Epub 2025 Apr 30. Braz J Otorhinolaryngol. 2025. PMID: 40305979 Free PMC article.
-
Polygonatum polysaccharides as gut microbiota modulators: implications for autophagy-dependent PD-L1 clearance in cancer immunotherapy.Front Nutr. 2025 Jun 24;12:1612644. doi: 10.3389/fnut.2025.1612644. eCollection 2025. Front Nutr. 2025. PMID: 40630164 Free PMC article. Review.
-
Characteristics of gut microbiota dysbiosis in patients with colorectal polyps.World J Gastrointest Oncol. 2025 Jan 15;17(1):98872. doi: 10.4251/wjgo.v17.i1.98872. World J Gastrointest Oncol. 2025. PMID: 39817124 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical